Add this result to my export selection FDA Alerts Healthcare Professionals About the Risk of Medication Errors with Tranexamic Acid Injection Resulting in Inadvertent Intrathecal (Spinal) Injection Source: US Food and Drug Administration - FDA (Remove filter) Published by US Food and Drug Administration, 03 December 2020 The FDA is warning of the risk of inadvertent intrathecal administration of tranexamic acid injection, in most cases given accidentally instead of the intended intrathecal anaesthetic. Cartons and... Read Summary Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection FDA Approval of setmelanotide (Imcivree) for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency Source: US Food and Drug Administration - FDA (Remove filter) Published by US Food and Drug Administration, 17 November 2020 Approval is based on phase III clinical data which showed that 80% of patients with obesity due to POMC or PCSK1 deficiency achieved >10% weight loss and 45.5% of patients with obesity due to LEPR... Read Summary SPS comment Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection FDA expands approval of uncomplicated influenza treatment Xofluza (baloxavir marboxil) to include post-exposure prevention Source: US Food and Drug Administration - FDA (Remove filter) Published by US Food and Drug Administration, 26 November 2020 FDA states expanded indication for this oral antiviral which prevents virus replication by inhibiting cap-dependent endonuclease, will provide important option to help prevent influenza just in time... Read Summary SPS comment Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection Coronavirus (COVID-19) Update: FDA Authorises Monoclonal Antibody for Treatment of COVID-19 Source: US Food and Drug Administration - FDA (Remove filter) Published by US Food and Drug Administration, 09 November 2020 The US FDA has issued an emergency use authorisation for investigational monoclonal antibody therapy bamlanivimab for treatment of mild-to-moderate COVID-19 in patients’ =12 years weighing = 40 kg... Read Summary SPS comment Type: Medicines Current Awareness (Remove filter)